Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of BL-B01D1 versus investigator's choice in previously platinum-treated advanced biliary tract cancer
CTR20261725Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in biliary cancer, sponsored by Biokin Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
biliary cancer
Beyond the preview
Go deeper on CTR20261725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261725.